Vés al contingut

“A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene

Obert
  • Codi protocol: BIA 28-6156-201
  • Codi EudraCT: No aplica
  • Grup de recerca: Malalties Neurodegeneratives
  • Servei: Neurologia
  • Investigador/a principal:  Hernández Vara, Jorge
  • Malaltia: Tumors
  • Fase: Fase II
  • Estat: Reclutant voluntaris